T he Sigma-1 receptor (Sigmar1) was first proposed as an opioid receptor subtype, 1 but subsequent studies showed it to be a unique intracellular protein that binds diverse classes of pharmacological compounds. 2 The potential physiological importance of Sigmar1 is implied by its association with many neurodegenerative diseases. [3] [4] [5] [6] [7] Recessive mutations in SIGMAR1 have been identified as a causative gene for amyotrophic lateral sclerosis with or without frontotemporal lobar degeneration, 4, 8 juvenile amyotrophic lateral sclerosis, 5, 9 and distal hereditary motor neuropathy. [10] [11] [12] [13] Subsequent studies showed that activation of Sigmar1 is protective in a variety of conditions, including activated chloride channels. 23 In addition, studies showed that Sigmar1 resides at the mitochondrion-associated endoplasmic reticulum (ER) membrane playing a role in regulating the Ca 2+ signaling between ER and mitochondria in Chinese hamster ovary cells. 24 Within the mitochondrion-associated ER membrane, activated Sigmar1 appears to stabilize inositol 1,4,5-trisphosphate receptors by protecting them from proteasomal degradation 24 and enhances inositol 1,4,5-trisphosphatedependent calcium release from ER by promoting their dissociation from the ion channel chaperone protein ankyrin B in Michigan Cancer Foundation-7 breast tumor cell lines. 19 In contrast, Sigmar1 inhibits store-operated Ca 2+ entry by attenuating STIM1 coupling to Orai1 by and reducing the Ca 2+ content of the ER stores in human embryonic kidney cells. 25 A recent study also showed that preincubation of macrophages with the Sigmar1 antagonist haloperidol leads to a significant inhibition of the store-dependent Ca 2+ entry induced by endoplasmic Ca 2+ -ATPase inhibitors in rat peritoneal macrophages. 26 Sigmar1 activation by the agonist 1,3-di-o-tolylguanidine and (+)-pentazocine decreases intracardiac ganglion neuron excitability by modulating voltage-gated Na + channels. 27 All these studies used in vitro cell culture experiments with Sigmar1 ligands (agonist and antagonists) to define the cellular function of Sigmar1. Because all previous studies using described Sigmar1 ligands such as fluvoxamine, 28 sertraline, 29 (+)pentazocine, 30 and haloperidol 31 involve serotonin reuptake inhibitors and also have wide affinity for other receptors, 32, 33 the role of Sigmar1 in the heart remains unclear despite a wealth of published literature.
The possible presence of Sigmar1 in cardiomyocytes was initially hypothesized based on experiments using radioligandbinding assays, with the data suggesting that cardiomyocytes exhibit binding sites for Sigmar1 ligands. 34, 35 Most studies addressing Sigmar1's function in cardiomyocytes have been limited to isolated heart preparations and indirect observations using nonspecific Sigmar1 ligands. [35] [36] [37] [38] [39] [40] For example, Sigmar1 ligands such as (+)-3-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine, (+)-pentazocine, and haloperidol were reported to alter contractility, calcium (Ca 2+ ) influx, and rhythmic activity in cultured cardiac myocytes. 35, 36, 38 Data from various studies were consistent with the hypothesis that Sigmar1 ligands can modulate cardiomyocyte contractility. We previously reported the distribution of Sigmar1 across different organs and noted abundant expression in the heart. 41 , 42 We also reported that pressure overload-induced hypertrophy significantly decreased the cardiac expression of Sigmar1 and found a significant correlation between heart dysfunction and decreased Sigmar1 expression in the left ventricle (LV). 14, [42] [43] [44] Treatment with the neurosteroid dehydroepiandrosterone or with pentazocine was cardioprotective in the context of pressure overload-induced cardiac dysfunction. Sigmar1 activation by treatment with fluvoxamine or SA4503 improved cardiac function and reduced cardiac hypertrophy in a transverse aortic constriction mouse model of cardiac injury. 14, [42] [43] [44] [45] [46] Moreover, Sigmar1 gene expression was upregulated in the heart by strong stress stimuli such as immobilization and hypoxia. 47 Despite a wealth of published literature, the role of Sigmar1 in the heart is unclear, as these compounds are serotonin reuptake inhibitors and have extensive affinity to other receptors. 32, 33 Two separate lines of Sigmar1 global gene-ablated (Sigmar1 À/À ) mice have been generated by gene targeting (Oprs1 tm1Lmon /Oprs1 tm1Lmon ) 48 or gene trapping (Oprs1 Gt(IRESBetageo)33Lex /Oprs1 Gt(IRESBetageo)33Lex ). 49 With both strategies, Sigmar1 homozygous knockout lines were viable, fertile, and did not display an overt phenotype compared with wild-type littermates, but these studies were limited to
Clinical Perspective
What Is New?
• The Sigma 1 receptor (Sigmar1) has emerged as an interorganelle signaling protein having multiple functions, but its physiological function remained unknown.
• Here we defined the physiological function of Sigmar1 in the heart. • This study shows that loss of Sigmar1 function led to mitochondrial dysfunction and abnormal mitochondrial architecture, ultimately leading to adverse cardiac remodeling.
• This study reveals a potential molecular function of Sigmar1 in regulating the mitochondrial bioenergetics that are essential to maintain normal cardiac contractile function.
What Are the Clinical Implications?
• Our study is the first to show the development of cardiac contractile dysfunction and cardiac fibrosis in Sigmar1
À/À mice with aging.
• We also found that the Sigmar1 À/À hearts develop significant accumulations of irregularly shaped mitochondria and defects in mitochondrial respiratory function.
• All these data demonstrate that Sigmar1 is needed to maintain normal cardiac contractility and encourage clinical research to evaluate the potential role of Sigmar1 in cardiovascular disease.
cursory observations of limited sample sizes. 48, 49 To date, no studies detailing the cardiac phenotype of these Sigmar1
À/À mice have been reported. In the present study using Sigmar1
À/ À mice, we studied the functional consequences of Sigmar1 ablation in regulating cardiac function, morphology, and ultrastructure. We also observed changes in mitochondrial dynamics and bioenergetics. Our results suggest the importance of Sigmar1 in regulating mitochondrial bioenergetics essential to maintain cardiac contractile function.
Materials and Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Other researchers may contact the corresponding author about the data and methodological questions.
Materials
The materials we used are the following: Cell Lytic M (SigmaAldrich, St. Louis, MO), Protease Inhibitor Cocktail (Roche, Basel, Switzerland), precast 7.5% to 15% Criterion Gels (BioRad, Hercules, CA), Alexa Fluor 488 wheat germ agglutinin kit (Invitrogen, Carlsbad, CA), 4 0 ,6-diamidino-2-phenylindole (Invitrogen), oligomycin (Sigma-Aldrich), carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone (FCCP) (Sigma-Aldrich), rotenone (Sigma-Aldrich), antimycin A (Sigma-Aldrich), Ponceau S (Acros Organics, Geel, Belgium), Calcium Green-5N (Invitrogen), and Vectashield Hardset (H1400; Vector Labs, Burlingame, CA).
Animals
The global Sigmar1 knockout (Sigmar1
) mice generated by gene trapping (Oprs1 Gt(IRESBetageo)33Lex /Oprs1
Gt(IRESBetageo) 33Lex ) 49 were obtained from the Mutant Mouse Resource Regional Center. Because these mice were in a mixed background (C57BL69129S/SvEv), we backcrossed with C57BL6 for 10 generations. Both male and female mice consisting of Sigmar1 À/À (n=70) and wild-type (Wt) (n=70) littermate control mice were used. All procedures for handling animals complied with the Guide for Care and Use of Laboratory Animals and were approved by the ACUC Committee of LSU Health Sciences Center-Shreveport. All animals were cared for according to the National Institutes of Health guidelines for the care and use of laboratory animals.
In Vivo Cardiac Function and b-Adrenergic Responsiveness
Invasive hemodynamic studies were performed in the intact animals as described. 50, 51 The right femoral artery and vein were cannulated with polyethylene tubing (PE-90) for measuring systemic arterial pressure. To assess myocardial performance, closed-chest animals were studied with a high-fidelity 1.4F Millar micromanometer-tipped catheter placed retrograde across the aortic valve into the LV (via right carotid cutdown). Hemodynamic parameters were determined during increasing doses of dobutamine using 3-minute constant infusions (0.1 lL/min per gram body weight), and the average value during the final 30 seconds of each infusion was used. Online heart rate, telemetry, and LV developed pressure and AEdP/dt, were archived on a Macintosh computer using Matlab software (Mathworks, Natick, MA), and the investigators were blinded to genotype.
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Echocardiography
Cardiac echocardiography was performed on isofluraneanesthetized mice with a VisualSonics Vevo 2100 Imaging System (Toronto, ON, Canada) using a 40-MHz transducer to assess cardiac functional parameters as described. 
Histological Analysis
Hearts from deeply anesthetized 6-month-old mice were harvested in diastole, fixed in 10% buffered formalin, and embedded in paraffin. Serial 5-lm heart sections from each group were stained with Masson trichrome 52, 53 and Sirius red. 52, 57 Fibrosis and collagen deposition within sections were quantitated using ImageJ software (National Institutes of Health, Bethesda, MD) as described previously. 50, 57 Fibrosis was quantified by blue-stained areas, and nonstained myocyte areas from each section using color-based thresholding. To quantitate collagen deposition, red-stained areas and nonstained myocyte areas were determined using color-based thresholding. The percentage of total fibrosis area was calculated as the blue-stained areas divided by total surface area from each section. The percentage of collagen deposition area was calculated as the red-stained areas divided by total surface area from each section. 52 
Wheat Germ Agglutinin Staining
Briefly, paraffin-embedded heart tissue sections (5 lmol/L) were dewaxed and hydrated, and antigen was retrieved by boiling at 100°C in 10 mmol/L sodium citrate buffer (pH 6) for 30 minutes. 52 The sections were then blocked with blocking solution (1% BSA, 0.1% cold water fish skin gelatin, and 1% Tween 20 in PBS) for 1 hour at room temperature followed by incubation with Alexa Fluor 488 wheat germ agglutinin (5 lg/mL, Invitrogen) and 4 0 ,6-diamidino-2-pheny- 
Transmission Electron Microscopy
For electron microscopic analysis, mice were anesthetized with isoflurane, and the hearts were sequentially first perfused with 1% paraformaldehyde and 2% glutaraldehyde in the cardioplegic buffer as described previously. 52, 53 Hearts were perfused with 1% paraformaldehyde and 2% glutaraldehyde in 0.1 mol/L cacodylate buffer (pH 7.2), postfixed in 1% OsO 4 , and processed for thin sectioning. Multiple sections were counterstained with uranium and lead salts and then examined with a Hitachi 7600 (Chiyoda, Tokyo, Japan) transmission electron microscope. Images were acquired with an AMT digital camera. Multiple sections were cut from 2 to 4 mice of mixed sex, and >20 fields were observed by a blinded observer. For the electron microscopic analysis, we used 2 mice for Sigmar1 À/À (male and female) and 2 mice for Wt (male and female). A blinded observer analyzed and quantitated 22 microscopic fields containing 1538 mitochondria for Sigmar1 À/À hearts and 21 microscopic fields containing 2537 mitochondria for Wt hearts to measure mitochondria size, area, density, and size distribution using ImageJ software (NIH). Mitochondrial density was measured by percentage of the areas taken by mitochondria compared to those of the cardiomyocytes.
ATP Measurements
Cellular and mitochondrial ATP contents were measured using the ATP Bioluminescence Assay Kit HS II (Roche) in freshly prepared whole-cell lysates and mitochondrial suspensions from hearts according to manufacturer's instructions. 52, 59, 60 Freshly excised hearts were homogenized using a glass/Teflon homogenizer (Wheaton, Millville, NJ) to prepare whole-cell and mitochondria lysates by methods described previously. 52 ATP content was measured on a FLUOstar OPTIMA microplate reader (BMG Labtech, Ortanberg, Germany), and ATP levels in samples were normalized to protein content as measured by Bio-Rad protein assay reagent.
52,59
Mitochondrial Electron Transport Chain Complex Activity Assays
Isolated mitochondria were used to measure mitochondrial electron transport chain complex activities spectrophotometrically, as described previously. [61] [62] [63] Complex I activity was determined by measuring NADH (100 lmol/L) oxidation at 340 nm for 2 minutes in an assay mixture containing 10 lg mitochondrial protein in 50 mmol/L potassium phosphate buffer (pH 7.5), 1 mg/mL BSA, 250 lmol/L KCN, and 60 lmol/L decylubiquinone in a 1-mL cuvette on a DS-11 FX+ spectrophotometer (DeNovix, Wilmington, DE). In parallel, NADH oxidation was measured in the presence of complex I inhibitor 10 lmol/L rotenone in the above assay mixture for 2 minutes. Specific complex I activity was calculated as rotenone-sensitive activity expressed as nanomoles/minute per milligram of mitochondrial protein. [61] [62] [63] Complex II activity was determined by measuring the reduction of 2,6-dichlorophenolindophenol coupled to complex II catalyzed reduction of decylubiquinone. Briefly, 5 lg mitochondrial protein in 50 mmol/L potassium phosphate buffer (pH 7.5), 1 mg/mL BSA, and 20 mmol/L succinate was incubated at 37°C for 10 minutes following measurement of 2,6-dichlorophenolindophenol reduction in 
Protein Extraction and Western Blot Analyses
Total proteins were prepared from hearts harvested and lysed with Cell Lytic M (Sigma-Aldrich) lysis buffer supplemented with Complete Protease Inhibitor Cocktail (Roche) as described previously. 52, 53 The heart homogenates were centrifuged at 14 000g for 15 minutes, and protein content of the soluble lysates was measured using the modified Bradford protocol/reagent relative to a BSA standard curve (BioRad). Protein lysates were separated on SDS-PAGE using precast 7.5% to 15% gels (BioRad) and transferred to polyvinylidene fluoride membranes (BioRad). Membranes were blocked for 1 hour in 5% nonfat dried milk and exposed to primary antibodies overnight. The following primary antibodies were used for immunoblotting: anti-Drp1 
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction Analysis
Total RNA was isolated with TRI reagent (Molecular Research Center) according to the manufacturer's protocol. Quantitative real-time polymerase chain reaction was performed with a CFX-96 instrument (Bio-Rad) using TaqMan probes (Applied Biosystems, Foster City, CA) for cardiac fetal genes (Nppa, Nppb, and Myh6; Applied Biosystems) as described previously. 53 Data were normalized to Gapdh (Applied Mitochondrial swelling assay was performed in isolated mitochondria as described previously. 52 Mitochondria isolated from hearts were suspended in swelling buffer (120 mmol/L KCl, 10 mmol/L Tris pH 7.4, 5 mmol/L KH 2 PO 4 ), 7 mmol/L pyruvate, 1 mmol/L malate, and 10 lmol/L EDTA. Mitochondrial swelling was induced by challenging the mitochondria with 200 lmol/L CaCl 2 , and the absorbance at 540 nm was monitored as described previously. 52 
Statistics
Data are expressed as meanAESEM. All statistical tests were done with GraphPad Prism software (La Jolla, CA). All data were tested for normality using the Kolmogorov-Smirnov test, and data that passed the normality assumption were analyzed using a Student t test (P<0.05) for 2 groups and groups of 3 or more with 1-way ANOVA, followed by the Tukey post hoc test. Hemodynamics data were analyzed using a mixed, 2-factor ANOVA with repeated measures on the second factor, and post hoc comparisons were performed by Bonferroni posttests. 51, 64, 65 For certain data sets with smaller sample sizes (n=3-6), the Kruskal-Wallis test was applied, and data were presented in graphs showing median and interquartile ranges. A value of P<0.05 was considered statistically significant.
Results
Sigmar1 Global Knockout Mouse
We obtained the global knockout mice generated by gene trapping (Oprs1
( Figure S1A ) 49 and backcrossed with C57BL6 for 10 generations because the commercially available mice are on a mixed background (C57BL69129S/SvEv). We confirmed Sigmar1 knockdown in the heart by Western blot analysis of the heart cell lysate ( Figure S1B ), using Wt littermate mice as controls.
Invasive Hemodynamic Assessment of Cardiac Function in the Sigmar1
À/À Mice Cardiac function was assessed at 3 to 4 months of age by LV catheterization both under basal conditions and after stimulation with increasing doses of the b 1 -adrenoceptor agonist dobutamine. At baseline, Sigmar1 À/À mice showed significantly increased systolic blood pressure compared with Wt controls ( Figure 1C ). Although Sigmar1 À/À mice showed slightly higher maximal LV pressure, mean arterial blood pressure, maximum rates of LV contraction (dP/dt max ) and relaxation (dP/dt min ), the differences were not statistically significant ( Figure 1 ). No differences were found in basal ( Figure 1A ) or dobutamine-stimulated heart rates within groups (Figure 2A) , suggesting that the changes in hemodynamic parameters were not due to intrinsic heart rate differences. At all doses of dobutamine, LV pressure, systolic blood pressure, and mean arterial pressure were significantly higher in Sigmar1 À/À compared with Wt, although in neither genotype did these parameters modulate in response to dobutamine dose. In both groups, dP/dt max increased with dobutamine, with the Sigmar1 
Cardiac Fibrosis in Sigmar1 À/À Mice
Because the Sigmar1 À/À hearts began to show significant cardiac contractile dysfunction by 6 months of age, we evaluated cardiac morphometry by histological analysis using light microscopy with Masson trichrome and Sirius red staining ( Figure 4A and 4B). Perivascular fibrosis was evident in the Sigmar1 À/À hearts ( Figure 4A and 4B), and expression of the fibrosis marker periostin was increased as well ( Figure 4C ). Heart weight-to-body weight ratios were measured as an indicator of cardiac hypertrophy and were not significantly different between Sigmar1 À/À and Wt groups at 6 months of age ( Figure 4D ). Expression of molecular markers of cardiac hypertrophy including natriuretic peptide A, natriuretic peptide B, and a myosin heavy chain was not significantly changed in Sigmar1 À/À hearts compared to Wt hearts at 6 months of age ( Figure 4E through 4G) . Cardiomyocyte size determined directly using wheat germ agglutinin staining of the LV demonstrated no significant difference between the 2 groups ( Figure 4H ). Thus, in addition to defective cardiac contractile function, the Sigmar1 À/À hearts eventually undergo adverse cardiac remodeling without any changes in cardiomyocyte size.
Sigmar1 Loss of Function Leads to Changes in Mitochondrial Ultrastructure
Previous studies have shown that both in vitro pharmacological inhibition of Sigmar1 and in vivo Sigmar1 knockdown resulted in a significant (%30%) increase in motor neuron mean mitochondrial size. 49 Accordingly, we examined mitochondrial ultrastructure by electron microscopy in Wt and Sigmar1 À/À mouse hearts. In 6-month-old Wt hearts, the mitochondria are well organized and in a regular pattern along the sarcomeres. In contrast, Sigmar1 À/À cardiomyocytes showed an irregularly shaped, highly fused mitochondrial network, and exhibited abnormal cristae ( Figure 5A ). Quantification analyses revealed that despite a lower absolute mitochondrial number ( Figure 5B ), the Sigmar1 À/À hearts had an overall increased average mitochondrial size (Figure 5C ) and mitochondrial area ( Figure 5D ). Consequently, the mitochondrial density in Sigmar1 À/À hearts as measured by percentage mitochondrial area per total area is higher than in Wt littermates ( Figure 5E ). The mitochondrial size distribution frequency curve shows a significantly increased percentage of large-size mitochondria in the Sigmar1 À/À hearts compared with Wt hearts ( Figure 5F ). Taken together, these data demonstrate the potential impact of Sigmar1 in regulating mitochondrial organization and morphology in the heart. To further explore this concept, we examined the expression of mitochondrial fission and fusion regulatory proteins in the whole cell and mitochondrial fraction isolated from Sigmar1 À/À and Wt mice at 3 and 6 months of age.
Phosphorylation of GTPase dynamin-related protein 1 (Drp1) at Ser637 in the Sigmar1 À/À hearts was significantly increased in the whole cell fraction ( Figure 6A and 6B). Drp1 phosphorylation at Ser616, total Drp1, and mitochondrial fusion regulatory protein OPA1 were unchanged in the whole-cell fraction of Sigmar1 À/À hearts compared to Wt hearts ( Figure 6A and 6B). During mitochondrial fission, Drp1 translocates from the cytosol to prospective fission sites on the mitochondrial surface. [66] [67] [68] Western blot and densitometric quantification showed decreased Drp1 in the Sigmar1 À/À mitochondrial fraction compared with Wt preparations. In contrast, mitochondrial fusion regulatory protein OPA1 in the 
, Heart rate (beats/min). B, Maximal LV pressure (LVP). C, Systolic blood pressure. D, Mean arterial blood pressure (MAP). E, Maximum rate of LV contraction (dp/dt max ). F, Maximum rate of LV relaxation (dP/dt min ). G, LV end-diastolic pressure (LVEDP). H, Relaxation time constant (s). All measurements were carried out using 3-to 4-month-old Sigmar1
À/À mice with littermate Wt mice used as controls (n=4 to 5 mice per group). Boxes represent interquartile ranges, lines represent medians, whiskers represent ranges, and P values were determined by KruskalWallis test. LV indicates left ventricle; NS, not significant; Wt, wild type.
Figure 2. Cardiac hemodynamics in the Wt and Sigmar1
À/À heart. Cardiovascular performance in anesthetized, closed-chest mice under baseline conditions and increasing doses of the b-adrenergic agonist dobutamine. At the conclusion of the dobutamine challenge, propranolol was delivered to produce complete badrenergic blockade. A, Heart rate (beats/min). B, Maximal LV pressure (LVP). C, Systolic blood pressure. D, Mean arterial blood pressure (MAP). E, Maximum rate of LV contraction (dp/dt max ). F, Maximum rate of LV relaxation (dP/dt min ). G, LV end-diastolic pressure (LVEDP). H, Relaxation time constant (s). All measurements were carried out using 3 to 4 month old Sigmar1 À/À mice with littermate Wt mice used as controls (n=4-5 mice per group). Values are meansAESEM. Data were analyzed using a mixed, 2-factor ANOVA with repeated measures on the second factor, and post hoc comparisons were performed by Bonferroni posttests. *P<0.05, **P<0.01, and ***P<0.001 between Sigmar1 À/À and Wt mouse for corresponding dose of dobutamine. # P<0.05 and ## P<0.01 represent significant group effect compared with Wt group. Dob indicates dobutamine; dp/dt, rate of change of pressure; LV, left ventricle; LVEDP, LV end-diastolic volume; LVP, LV pressure; MAP, mean arterial pressure; NS, not significant; Pro, Propranolol; Wt, wild type.
mitochondrial fraction was significantly increased in the Sigmar1
À/À hearts ( Figure 6C and 6D) . To confirm the purity of the mitochondrial fractionation, we used GAPDH protein expression in the cytosolic fraction as a positive control and absence of GAPDH in the mitochondrial fraction as measures of purity. Western blots using the same membrane for COXIV were used to confirm the mitochondrial extracts. Ponceau S protein staining of the transfer membrane confirmed approximately equal loading and transfer across the gel. Similarly, we also observed significantly increased Drp1 phosphorylation at Ser637 in the Sigmar1 À/À hearts at 6 months of age. OPA1 expression was also significantly increased in the whole cell fraction of Sigmar1 À/À hearts compared with Wt hearts (Figure 7A and 7B). Western blot and densitometric quantification showed a decreased level of Drp1 in the Sigmar1 À/À mitochondrial fraction compared to Wt. In contrast, OPA1 levels in the mitochondrial fraction were significantly increased in the Sigmar1 À/À hearts ( Figure 7C and 7D). Therefore, the Sigmar1 À/À mouse hearts showed altered expression of regulatory proteins that impact on mitochondrial dynamics and structural changes that might impact overall respiratory functions.
Mitochondrial Respiratory Dysfunction in the Sigmar1 À/À Hearts
To explore functional alterations directly, we isolated mitochondria from 3-and 6-month-old Sigmar1 À/À and Wt consuming processes was estimated by inhibiting the respiratory chain with rotenone and antimycin A and was not affected in Sigmar1 À/À mitochondria ( Figure 8E ). The respiratory reserve capacity, calculated by subtracting basal OCR from FCCP-stimulated OCR, was significantly lower in Sigmar1 À/À mitochondria ( Figure 8F ) and ATP turnover, measured by nonmitochondrial respiration subtracted from the ATP-linked OCR, was significantly decreased in Sigmar1 À/À mitochondria ( Figure 8G ). The maximum respiration calculated by nonmitochondrial respiration subtracted from FCCP-stimulated OCR was also significantly lower in Sigmar1 À/À mitochondria ( Figure 8H ). The proton leak across the inner mitochondrial membrane, represented by nonmitochondrial respiration subtracted from the postoligomycin OCR, was significantly increased in Sigmar1 À/À mitochondria ( Figure 8I ) at 6 months of age. We conclude that mitochondria isolated from Sigmar1 À/À hearts are functionally compromised compared with normal cardiac mitochondria. Because the Sigmar1 À/À hearts showed defective mitochondrial respiration, we compared oxidative phosphorylation protein levels in whole-cell lysates using 3-and 6-month-old Sigmar1 À/À and Wt mixed-sex mouse hearts. Sigmar1 hearts showed significantly increased levels of Complex I, II, and III, but Complex V expression was unchanged ( Figure 10A and 10B). We also found significantly increased expression of the E2, E3bp, and E1a/b subunit of PDH complex proteins ( Figure 10C and 10D) . Ponceau S staining of proteins was used to visualize loading. Measurement of mitochondrial and cellular ATP levels demonstrated a significantly lower ATP pool in Sigmar1 À/À hearts ( Figure 10E ). To determine possible involvement of mitochondrial Ca 2+ handling, we measured mitochondrial Ca 2+ uptake and swelling in isolated mitochondria from 6-month-old Sigmar1 À/À and Wt mouse hearts. We used Calcium Green-5N to measure mitochondrial Ca 2+ uptake. 52 Ca 2+ pulses of 20 nmol/mg of mitochondrial protein resulted in a rapid increase in Calcium Green-5N fluorescence followed by a decline in the fluorescence intensity corresponding to mitochondrial Ca 2+ uptake ( Figure 11A ). With increasing mitochondrial Ca 2+ loading, extramitochondrial Ca 2+ accumulates until the addition of Ca 2+ leads to a sustained Ca 2+ increase indicating a massive release of mitochondrial Ca 2+ . 52 The Sigmar1 À/À heart mitochondria showed similar mitochondrial Ca 2+ retention capacity to Wt mitochondria ( Figure 11A ). Mitochondrial swelling determined by challenging isolated mitochondria with Ca 2+ and measuring the decrease in light scattering also showed similar mitochondrial swelling in both groups of mice at 6 months of age ( Figure 11B ). These data suggest that the mitochondrial Ca 2+ handling was not altered in the Sigmar1 À/ À hearts. Collectively, we find that the defective mitochondrial respiration in the Sigmar1 À/À hearts is associated with altered expression of oxidative phosphorylation and pyruvate dehydrogenase proteins.
, LV diastolic internal dimension (LVID;d). B, LV systolic internal dimension (LVID;s). C, Percentage fractional shortening (%FS). D, LV diastolic volume (LVVol;d). E, LV systolic volume (LV Vol;s). F, Percentage ejection fraction (%EF). G, LV diastolic interventricular septum thickness (IVS;d). H, LV diastolic
Discussion
Given the significance of Sigmar1 in neurological diseases, in the present study we wished to define the physiological role of Sigmar1 in the heart. Our study is the first to show the development of cardiac contractile dysfunction and structural cardiac deficits in Sigmar1 À/À hearts during aging. We also and (D) densitometric quantification of the expression of mitochondrial dynamic regulatory proteins in the mitochondrial fraction of Wt and Sigmar1 À/À hearts: Drp1 and OPA1. Drp1 overexpressing HEK293 cells was used as a positive control for Drp1, and b-actin was used on the same membrane. Cytosol fraction was used as a control to show purity of the mitochondrial fraction and confirmed by GAPDH. COXIV was run on the same membrane to confirm mitochondrial extracts. Ponceau S protein staining of the transfer membrane confirmed approximately equal loading across the gel (n=4 mice per group). Boxes represent interquartile ranges, lines represent medians, whiskers represent ranges, and P values were determined by Kruskal-Wallis test. NS indicates not significant; Wt, wild type. found that the Sigmar1 À/À hearts develop significant cardiac fibrosis, accumulation of irregularly shaped mitochondria, and show defective mitochondrial respiratory function compared with to Wt hearts. All these data demonstrate a potential function of Sigmar1 in regulating regular mitochondrial organization and respiration directly or indirectly.
Earlier studies showed that exposure of isolated adult rat cardiomyocytes to a Sigmar1 ligand (eg, haloperidol) caused a marked concentration-dependent increase in the amplitude of cell contraction. 38 Our in vivo assessment of cardiac hemodynamics in young Sigmar1 À/À mice showed that contractility was similar to that in Wt littermates at baseline, but stimulation with increasing doses of dobutamine resulted in increased contractility. Likewise, our echocardiographic analysis of 3-month-old mice did not show a significant difference in the basal cardiac function of Sigmar1 À/À mice, but aging Sigmar1 À/À hearts gradually developed increased systolic LV dimension and a decline in cardiac LV function. Furthermore, this dysfunction was accompanied by cardiac fibrosis in 6-month-old Sigmar1 À/À hearts.
Balanced mitochondrial fission and fusion are indispensable to maintain normal mitochondrial network morphology and meet the metabolic needs of the cell. Sigmar1 À/À hearts showed irregularly shaped highly fused large mitochondria, suggesting impairment of mitochondrial dynamics. During mitochondrial fission, the dynamin-related GTPase Drp1 is normally recruited from the cytosol into the mitochondrial outer membrane. The mitochondrial fission-promoting activity of Drp1 is controlled by Ser637 phosphorylation, which inhibits the Drp1 translocation to mitochondrial fission sites. 69 We found that Ser637 phosphorylation was significantly increased in the Sigmar1 À/À cardiac cell lysates, and 71 Studies have also shown a positive correlation between mitochondrial structural abnormalities and alterations in mitochondrial metabolic and bioenergetic functions including decreased respiration and ATP production in the development of hypertension. 71 Despite the link between damaged mitochondria and high blood pressure in the Sigmar1 À/À mice, a cause-effect relationship remains to be established. In future studies we aim to confirm the role of cardiac Sigmar1 in the development of high blood pressure using a cardiac-specific Sigmar1 knockout mouse. Although Sigmar1 À/À hearts showed markedly abnormal mitochondrial respiration at 6 months, neither the ultrastructure of the heart nor the molecular markers of hypertrophy were deranged, which is consistent with only mildly decreased LV systolic function as manifested by decreased fractional shortening as well as ejection fraction. Therefore, Sigmar1 À/À young mice, despite having abnormal mitochondrial function, seem to be able to compensate for unfavorable bioenergetics. Compensation is sustained to a large degree even up to 6 months, at which time we observed a mild decrease in LV systolic function, but histology demonstrated only mild perivascular and interstitial fibrosis without activation of molecular markers of hypertrophy or increased cardiomyocyte cross-sectional area. In future studies we aim to determine the molecular function and mechanism of Sigmar1 in the heart by a cardiomyocyte-specific Sigmar1 knockdown in adult hearts to rule out possible compensatory changes at early ages.
Despite extensive studies, Sigmar1's subcellular localization and transmembrane topology remain obscure. Subcellular fractionation of neural tissues from mutant superoxide dismutase-1 transgenic mice showed Sigmar1 accumulation in mitochondrial fractions. 9 Immunoelectron microscopic data from the Mavlyutov group showed Sigmar1's subcellular localization to largely depend on cell and organ type. [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] For example, Sigmar1 localized to the nuclear envelope in photoreceptor cells 74 and in the nucleoplasmic reticulum as well as in the nucleus in the NSC34 cell line. 82 Surprisingly, immunoelectron microscopy was unable to detect Sigmar1at the plasma membrane. [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] Conflicting data exist regarding the localization of the Sigmar1 C-and N-termini, with the Mavlyutov group showing the C-terminus to reside inside the ER lumen and the N-terminus in the cytosol. 84 In contrast, the recently derived crystal structure proposes that the Cterminus resides on the cytosolic side of the ER. 85 These findings suggest a possible organ-specific localization and function for Sigmar1. Further studies are required to define Sigmar1's subcellular distribution and pathophysiological role in general and with cardiac injury more specifically.
Sigmar1 À/À mice were reported to develop multiple neuronal phenotypes-locomotor defects, 75 significant nerve denervation, 49 loss of motor neurons, 49 age-dependent motor phenotype and to show a depressive-like behavior. 48, 86 Sigmar1 À/À mice also showed disruption of intracellular Ca 2+ homeostasis, reduction in Ca 2+ flux into the mitochondria, and lower ATP content in neuronal cells. 9, 49, 75 Despite all these studies, there are no data dealing with the cardiac phenotype of Sigmar1 À/À mice. The present study highlights the structure-function relationships concerning Sigmar1's role in maintaining healthy cardiac function. Ours are the first in vivo data that bear on the structural and functional implications of the physiological functions of Sigmar1 in the heart. A significant limitation of our study is the use of global knockout mice in which we cannot rule out a cardiac impact of loss of Sigmar1 in other organs. We also do not know whether decreased mitochondrial bioenergetics underlies the morphological changes or is the result of deranged dynamics. Future studies are required to recapitulate these data using a cardiomyocyte-specific knockout mouse. However, significant alterations in dynamics regulatory protein expression and suppression of mitochondrial respiration as early as 3 months in the Sigmar1 À/À mouse hearts suggest that mitochondrial dysfunction led to cardiac dysfunction. Sigmar1 has a significant therapeutic potential for cardiovascular disease as reflected by two Sigmar1 ligands already appear in clinical trials: cutamesine (SA4503) for ischemic stroke (phase 2) 87 and SADHART-CHF (Sertraline for Depression in Patients with Heart Failure). [88] [89] [90] [91] [92] [93] [94] [95] [96] The SADHART-CHF study demonstrated that depression remission by sertraline may improve cardiovascular outcomes in patients with chronic heart failure 95, 96 but ignored sertraline's direct effect on cardiac Sigmar1 (if any). Moreover, a secondary analysis of the ENRICHD (Enhancing Recovery in Coronary Heart Disease) clinical trial showed that antidepressant treatment with the specific serotonin reuptake inhibitor sertraline (having Sigmar1 agonist activity in the nanomolar range) was associated with >40% reduction in the relative adjusted risk of death and reinfarction. 14 
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